Plus Therapeutics to Provide Business Update Call on June 30, 2026

HOUSTON, June 23, 2026 — Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today announced that management will host a business update conference call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time.

During the call, management will focus on the Company’s CNSide® diagnostic launch and its integrated development plan for lead drug Reyobiq. Furthermore, management will provide further detail on its CNS oncology strategy and native artificial intelligence development plans.

“Our team is making substantial progress in all 3 areas of the company, specifically diagnostics, therapeutics and artificial intelligence,” said Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “We are excited to provide an update on our progress toward our milestones and vision for the company to enable better outcomes for CNS oncology patients and provide long-term value creation for stockholders.”

Conference Call and Webcast Details

Date:

Tuesday, June 30, 2026

Time:

8:30 a.m. Eastern Time

Webcast:

Link

Dial-in (U.S./Canada):

1-888-349-0106

Dial-in (International):

1-412-317-6789

A replay of the webcast will be available following the event in the Investor Relations section of the Company’s website at www.plustherapeutics.com.

About Plus Therapeutics

Plus Therapeutics is a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for CNS cancers. The Company’s lead therapeutic platform is anchored by REYOBIQ™, and its diagnostics strategy includes the CNSide® cerebrospinal fluid assay platform, which is designed to support the management of patients with CNS cancers. Plus is also advancing an integrated data strategy intended to connect therapeutic, diagnostic, and bioinformatic insights across its CNS oncology programs.

Investor Contact

CORE IR [email protected]